ATAD3B Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatocellular carcinoma cell line, engineered to disrupt the ATAD3B gene. This pooled targeting approach generates a heterogeneous population of cells with targeted gene disruption, enabling functional studies of ATAD3B in a liver cancer context. The product avoids clonal isolation bottlenecks and provides a practical, scalable resource for investigating mitochondrial biology in hepatocellular carcinoma.
The SK-HEP-1 cell line, originally established from the ascites of a patient with liver adenocarcinoma, serves as a vital model for hepatocarcinogenesis and metastasis. Notably, these cells display both epithelial and endothelial characteristics, reflecting their plasticity and relevance to tumor microenvironment interactions. SK-HEP-1 cells are extensively employed to examine liver cancer cell migration, invasion, and mitochondrial dysfunction, making them a suitable host for studying ATAD3B-related mitochondrial perturbations.
ATAD3B encodes a mitochondrial inner membrane ATPase that forms complexes with ATAD3A, the MICOS complex, and HSP60, contributing to mitochondrial structure and function. It transcriptionally responds to upstream regulators NRF1, PPARGC1A, and HIF1A, and is activated by mitochondrial stress signals. ATAD3B regulates downstream targets including mtDNA copy number and intracellular cholesterol levels, while its interaction with VDAC, STAR, BAX, and cytochrome c positions it at the nexus of mitochondrial cholesterol metabolism and apoptosis. Mechanistically, ATAD3B promotes mitochondrial integrity and cholesterol trafficking, and its loss of function may impair these processes, sensitizing cells to apoptotic stimuli via cytochrome c release and caspase activation.
In hepatocellular carcinoma, mitochondrial function is frequently dysregulated, contributing to metabolic reprogramming and apoptosis resistance. The ATAD3B knockout in SK-HEP-1 cells provides a relevant model to dissect how loss of this ATPase disrupts mitochondrial cholesterol homeostasis, potentially enhancing sensitivity to intrinsic apoptosis and altering cellular responses to chemotherapeutic agents. This system allows investigation of ATAD3B??s role in sustaining mitochondrial membrane potential and mtDNA maintenance in a liver cancer background, offering insights into its contribution to cancer cell survival and metastasis.
Researchers can employ this polyclonal knockout model for a range of studies, including evaluating mitochondrial dysfunction via JC-1 membrane potential assays, quantifying apoptosis through Annexin V staining, and assessing cholesterol metabolism using biochemical quantification kits. It facilitates screening of mitochondrial-targeted therapeutics and elucidation of drug resistance mechanisms. Standard validation techniques such as Western blotting, RT-qPCR, and immunofluorescence enable confirmation of ATAD3B disruption. Its use in hepatocellular carcinoma research extends to examining mitochondrial fission/fusion dynamics and the unfolded protein response. For further inquiries or technical support, please contact Ascent Research.
